[go: up one dir, main page]

CL2016002873A1 - Composición farmacéutica para reducir el daño talámico. - Google Patents

Composición farmacéutica para reducir el daño talámico.

Info

Publication number
CL2016002873A1
CL2016002873A1 CL2016002873A CL2016002873A CL2016002873A1 CL 2016002873 A1 CL2016002873 A1 CL 2016002873A1 CL 2016002873 A CL2016002873 A CL 2016002873A CL 2016002873 A CL2016002873 A CL 2016002873A CL 2016002873 A1 CL2016002873 A1 CL 2016002873A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
damage
thalamic damage
reduce
reduce thalamic
Prior art date
Application number
CL2016002873A
Other languages
English (en)
Inventor
Massimo Filippi
Giancarlo Comi
Maria Assunta Rocca
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of CL2016002873A1 publication Critical patent/CL2016002873A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)

Abstract

COMPOSICION FARMACEUTICA QUE COMPRENDE LAQUINIMOD PARA EL USO EN INHIBIR O REDUCIR DAÑO TALAMICO EN VALOR DE REFERENCIA EN UN SUJETO AFECTADO CON UNA ENFERMEDAD O TRASTORNO DIFERENTE A UNA FORMA DE ESCLEROSIS MULTIPLE O UN SINDROME CLINICAMENTE AISLADO, O PARA INHIBIR O REDUCIR TEMBLORES O ESPASTICIDAD.
CL2016002873A 2012-10-12 2016-11-11 Composición farmacéutica para reducir el daño talámico. CL2016002873A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261713256P 2012-10-12 2012-10-12

Publications (1)

Publication Number Publication Date
CL2016002873A1 true CL2016002873A1 (es) 2017-04-17

Family

ID=50475887

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015000732A CL2015000732A1 (es) 2012-10-12 2015-03-23 Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica.
CL2016002873A CL2016002873A1 (es) 2012-10-12 2016-11-11 Composición farmacéutica para reducir el daño talámico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2015000732A CL2015000732A1 (es) 2012-10-12 2015-03-23 Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica.

Country Status (18)

Country Link
US (2) US20140107154A1 (es)
EP (1) EP2961406A4 (es)
JP (1) JP2015533163A (es)
KR (1) KR20150080509A (es)
CN (1) CN105263325A (es)
AR (1) AR092993A1 (es)
AU (2) AU2013329348A1 (es)
BR (1) BR112015007782A2 (es)
CA (1) CA2884272A1 (es)
CL (2) CL2015000732A1 (es)
EA (1) EA201590726A1 (es)
HK (1) HK1218865A1 (es)
IL (1) IL237745A0 (es)
MX (1) MX2015004564A (es)
PE (1) PE20151435A1 (es)
SG (1) SG11201501874TA (es)
TW (1) TW201420101A (es)
WO (1) WO2014058979A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161935B2 (en) 2012-02-03 2015-10-20 Teva Pharmaceutical Industries, Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
AR090073A1 (es) 2012-02-16 2014-10-15 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EP2956137A4 (en) * 2013-02-15 2016-08-03 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
BR112016014507A2 (pt) * 2013-12-20 2018-05-22 Teva Pharma uso de laquinimod para retardar progressão da doença de huntington
UY36099A (es) 2014-04-29 2016-02-29 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
AU2017326261A1 (en) * 2016-09-13 2019-04-04 Intekrin Therapeutics, Inc. Treatment of multiple sclerosis with CHS-131
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂
CN113397757A (zh) * 2021-06-07 2021-09-17 温州医科大学 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006204699B2 (en) * 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
WO2008009407A2 (en) * 2006-07-17 2008-01-24 Novartis Ag Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators
TW201438738A (zh) * 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
HUE026406T2 (en) * 2009-06-19 2016-06-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
ES2731052T3 (es) * 2009-08-10 2019-11-13 Active Biotech Ab Tratamiento de la enfermedad de Huntington usando laquinimod
EP2523668A1 (en) * 2010-01-13 2012-11-21 Ramot at Tel-Aviv University Ltd Treatment of multiple sclerosis
JP2013544887A (ja) * 2010-12-07 2013-12-19 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症患者において疲労を軽減し、機能状態を改善し、生活の質を改善するための、ラキニモド（ｌａｑｕｉｎｉｍｏｄ）の使用
JP5767393B2 (ja) * 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
SG11201401330YA (en) * 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple

Also Published As

Publication number Publication date
PE20151435A1 (es) 2015-10-15
US20160296511A1 (en) 2016-10-13
SG11201501874TA (en) 2015-05-28
CN105263325A (zh) 2016-01-20
WO2014058979A3 (en) 2015-08-20
BR112015007782A2 (pt) 2017-07-04
EP2961406A4 (en) 2017-01-04
KR20150080509A (ko) 2015-07-09
EA201590726A1 (ru) 2015-10-30
JP2015533163A (ja) 2015-11-19
AU2017203896A1 (en) 2017-06-29
WO2014058979A8 (en) 2015-04-16
HK1218865A1 (zh) 2017-03-17
EP2961406A2 (en) 2016-01-06
US20140107154A1 (en) 2014-04-17
WO2014058979A2 (en) 2014-04-17
CL2015000732A1 (es) 2015-08-07
IL237745A0 (en) 2015-05-31
CN105263325A8 (zh) 2017-07-14
AR092993A1 (es) 2015-05-13
MX2015004564A (es) 2015-07-21
AU2013329348A1 (en) 2015-05-28
TW201420101A (zh) 2014-06-01
CA2884272A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
CL2016002873A1 (es) Composición farmacéutica para reducir el daño talámico.
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
IL244240B (en) Aminoheteroaryl benzamides as kinase inhibitors
BR112015002738A2 (pt) composto , e , composição farmacêutica
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
CL2014002589A1 (es) Compuestos inhibidores de beta-lactamasas derivados de 7-oxo-1,6-diazabiciclo[3.2.1] octano; composicion farmaceutica que los comprende y uso para tratar una infeccion bacteriana.
GB2529325B (en) Multi-tenancy support for enterprise social business computing
EP3059271A4 (en) Fluorine-containing compound, composition for forming hard coat layer, and article having hard coat layer
MX2013012000A (es) Composicion y metodo para formar una superficie auto-descontaminante.
HUE045492T2 (hu) Porlasztható, helyileg alkalmazható hordozóanyag és foszfatidilkolint tartalmazó készítmény
BR112014016635A2 (pt) composto, composição, e, uso de um composto
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
DK2868318T4 (da) Injicerbar formulering
EP3000094A4 (en) Medication workflow management
EP2976400C0 (fr) Composition d'allophanate
CL2016001570A1 (es) Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas
GB201517616D0 (en) Social project management
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
GB2500292B (en) Hash-based Managing of Storage Identifiers
HRP20130082A2 (hr) Farmaceutski pripravak za produljeno oslobađanje trimetazidina
BR112014032501A2 (pt) composto, e, composição farmacêutica.
BR112014000232A2 (pt) primeira composição, segunda composição e artigo
BR112015002646A2 (pt) composto e composição farmacêutica
BR112013019061A2 (pt) composto inibidor da caspase-2, composição farmacêutica e uso de um composto
ZA201504080B (en) Combination medicament comprising phenylephrine and paracetamol